BridgeMD
Tests treatment safety and results for Non Small Cell Lung Cancer
Official title Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC
ClinicalTrials.gov ID: NCT03769129
What this study is testing
What is Pembrolizumab?
Pembrolizumab is an investigational medicine, being studied as a potential treatment for non small cell lung cancer.
Also referred to as Keytruda.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a prospective, randomized, single clinical study designed to evaluate its safety and efficacy by using Microwave Ablation combine with Pembrolizumab in patients with Stage ⅢB-Ⅳ Non-small Cell Lung.Cancer (NSCLC) who failed with first-line therapy.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Pathologically diagnosed IIIB or IV non-small cell lung cancer.
- Previously accepted first-line standard treatment failure or recurrence
- At least one measurable lesion.
- The patient has not received any other anti-cancer treatment within four weeks.
- Any gender, age ≥18 years
You likely can't join if
- Patients with two or more kinds of tumors.
- Patients with active viral or bacterial infection, and have failed to be controlled by anti-infective treatment.
- Patients with seropositive response of Human immunodeficiency virus (HIV) and syphilis, or fail to control the hepatitis B virus or hepatitis C virus...
- Patients with active rheumatic diseases, organ transplantation and other diseases affecting the immune system seriously.
- Patients with severe heart and lung dysfunction.
- Patients with severe chronic diseases of kidney, liver and other important organs.
See the full eligibility criteria
- Pathologically diagnosed IIIB or IV non-small cell lung cancer.
- Previously accepted first-line standard treatment failure or recurrence
- At least one measurable lesion.
- The patient has not received any other anti-cancer treatment within four weeks.
- Any gender, age ≥18 years
- ECOG PS : 0-2 points
- Expected survival ≥ 6 months
- The level of organ function meets the following criteria. (1) subject to the standard blood test: ANC ≥ 1.5×109 / L, PLT ≥ 50×109 / L, Hb ≥ 90g/L. (2) biochemical tests must meet the following criteria: TBIL\<1.5×ULN...
- Patients with two or more kinds of tumors.
- Patients with active viral or bacterial infection, and have failed to be controlled by anti-infective treatment.
- Patients with seropositive response of Human immunodeficiency virus (HIV) and syphilis, or fail to control the hepatitis B virus or hepatitis C virus infection.
- Patients with active rheumatic diseases, organ transplantation and other diseases affecting the immune system seriously.
- Patients with severe heart and lung dysfunction.
- Patients with severe chronic diseases of kidney, liver and other important organs.
- Patients with any other serious illness that the investigators consider it will may affect the patient's treatments, follow-up or assessment, including any uncontrolled clinically significant neurological or psychiatric...
- Patients who take part in clinical trials of other drugs or biological therapy at present or within 30 days before enrollment.
- Patients who need long-term use of immunosuppressive drugs or patients who are undergoing treatment of autoimmune diseases.
- Patients who need long-term use of glucocorticoid.
- Women patients in gestation period or suckling period.
The study team makes the final eligibility decision.
Where it's taking place
- Guangzhou, Guangdong, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Guangzhou, Guangdong, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.